McKesson, the largest U.S. pharmaceutical distributor, continues to face obstacles as the tailwind from branded drug price inflation subsides and customers look elsewhere. But its management isn't taking the news lying down. A series of acquisitions, ongoing restructuring, and a rash of new deals are helping lessen the blow, setting in motion a roller-coaster ride of a year. McKesson was founded in 1833 and is headquartered in San Francisco.
Company Info
| CEO | John H. Hammergren |
| CEO Title | Chairman, President & Chief Executive Officer |
| Sector | Wholesalers |
| Industry | Wholesalers: Health Care |
| HQ Location | San Francisco, CA |
| Website | www.mckesson.com |
| Years on Fortune 500 List | 23 |
| Employees | 68,000 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $192,487 |
| Profits ($M) | $2,258 |
| Assets ($M) | $56,563 |
| Total Stockholder Equity ($M) | $8,924 |
| Market Value — as of March 31, 2017 ($M) | $31,439 |
Profit Ratios
| Profit as % of Revenues | 1.2% |
| Profits as % of Assets | 4% |
| Profits as % of Stockholder Equity | 25.3% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 10 |
| EPS % Change (from 2015) | 54.7% |
| EPS % Change (5 year annual rate) | 16.2% |
| EPS % Change (10 year annual rate) | 15.1% |
Total Return
| Total Return to Investors (2016) | -28.3% |
| Total Return to Investors (5 year, annualized) | 13.3% |
| Total Return to Investors (10 year, annualized) | 11.6% |
